Asset Details
Do you wish to reserve the book?
Telitacicept: First Approval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Telitacicept: First Approval
Do you wish to request the book?
Telitacicept: First Approval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Telitacicept: First Approval
2021
Overview
Telitacicept (Tai'ai
®
) is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept is being developed by Yantai Rongchang Pharmaceutical through its subsidiary RemeGen for the treatment of B cell-mediated autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and multiple sclerosis (MS). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. In March 2021, telitacicept received its first approval in China for the treatment of patients with active SLE. Clinical studies of telitacicept in several other indications, including IgA nephropathy, MS, myasthenia gravis, neuromyelitis optica spectrum disorders, RA and Sjögren's syndrome are underway in China. This article summarizes the milestones in the development of telitacicept leading to this first approval for SLE.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Arthritis, Rheumatoid - drug therapy
/ B-Cell Activating Factor - drug effects
/ China
/ Disease
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Ligands
/ Lupus
/ Lupus Erythematosus, Systemic - drug therapy
/ Medicine
/ Multiple Sclerosis - drug therapy
/ Plasma
/ Proteins
/ Recombinant Fusion Proteins - therapeutic use
/ Steroids
/ Systemic lupus erythematosus
/ Tumor Necrosis Factor Ligand Superfamily Member 13 - drug effects
We currently cannot retrieve any items related to this title. Kindly check back at a later time.